Cargando…
Nanoencapsulated Doxorubicin Prevents Mucositis Development in Mice
Doxorubicin (DOX), a chemotherapy drug successfully used in the therapy of various types of cancer, is currently associated with the mucositis development, an inflammation that can cause ulcerative lesions in the mucosa of the gastrointestinal tract, abdominal pain and secondary infections. To incre...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329927/ https://www.ncbi.nlm.nih.gov/pubmed/34371713 http://dx.doi.org/10.3390/pharmaceutics13071021 |
_version_ | 1783732596672299008 |
---|---|
author | Pinto, Cristiane M. Horta, Laila S. Soares, Amanda P. Carvalho, Bárbara A. Ferreira, Enio Lages, Eduardo B. Ferreira, Lucas A. M. Faraco, André A. G. Santiago, Helton C. Goulart, Gisele A. C. |
author_facet | Pinto, Cristiane M. Horta, Laila S. Soares, Amanda P. Carvalho, Bárbara A. Ferreira, Enio Lages, Eduardo B. Ferreira, Lucas A. M. Faraco, André A. G. Santiago, Helton C. Goulart, Gisele A. C. |
author_sort | Pinto, Cristiane M. |
collection | PubMed |
description | Doxorubicin (DOX), a chemotherapy drug successfully used in the therapy of various types of cancer, is currently associated with the mucositis development, an inflammation that can cause ulcerative lesions in the mucosa of the gastrointestinal tract, abdominal pain and secondary infections. To increase the safety of the chemotherapy, we loaded DOX into nanostructured lipid carriers (NLCs). The NLC–DOX was characterized by HPLC, DLS, NTA, Zeta potential, FTIR, DSC, TEM and cryogenic-TEM. The ability of NLC–DOX to control the DOX release was evaluated through in vitro release studies. Moreover, the effect of NLC–DOX on intestinal mucosa was compared to a free DOX solution in C57BL/6 mice. The NLC–DOX showed spherical shape, high drug encapsulation efficiency (84.8 ± 4.6%), high drug loading (55.2 ± 3.4 mg/g) and low average diameter (66.0–78.8 nm). The DSC and FTIR analyses showed high interaction between the NLC components, resulting in controlled drug release. Treatment with NLC–DOX attenuated DOX-induced mucositis in mice, improving shortening on villus height and crypt depth, decreased inflammatory parameters, preserved intestinal permeability and increased expression of tight junctions (ZO-1 and Ocludin). These results indicated that encapsulation of DOX in NLCs is viable and reduces the drug toxicity to mucosal structures. |
format | Online Article Text |
id | pubmed-8329927 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83299272021-08-04 Nanoencapsulated Doxorubicin Prevents Mucositis Development in Mice Pinto, Cristiane M. Horta, Laila S. Soares, Amanda P. Carvalho, Bárbara A. Ferreira, Enio Lages, Eduardo B. Ferreira, Lucas A. M. Faraco, André A. G. Santiago, Helton C. Goulart, Gisele A. C. Pharmaceutics Article Doxorubicin (DOX), a chemotherapy drug successfully used in the therapy of various types of cancer, is currently associated with the mucositis development, an inflammation that can cause ulcerative lesions in the mucosa of the gastrointestinal tract, abdominal pain and secondary infections. To increase the safety of the chemotherapy, we loaded DOX into nanostructured lipid carriers (NLCs). The NLC–DOX was characterized by HPLC, DLS, NTA, Zeta potential, FTIR, DSC, TEM and cryogenic-TEM. The ability of NLC–DOX to control the DOX release was evaluated through in vitro release studies. Moreover, the effect of NLC–DOX on intestinal mucosa was compared to a free DOX solution in C57BL/6 mice. The NLC–DOX showed spherical shape, high drug encapsulation efficiency (84.8 ± 4.6%), high drug loading (55.2 ± 3.4 mg/g) and low average diameter (66.0–78.8 nm). The DSC and FTIR analyses showed high interaction between the NLC components, resulting in controlled drug release. Treatment with NLC–DOX attenuated DOX-induced mucositis in mice, improving shortening on villus height and crypt depth, decreased inflammatory parameters, preserved intestinal permeability and increased expression of tight junctions (ZO-1 and Ocludin). These results indicated that encapsulation of DOX in NLCs is viable and reduces the drug toxicity to mucosal structures. MDPI 2021-07-04 /pmc/articles/PMC8329927/ /pubmed/34371713 http://dx.doi.org/10.3390/pharmaceutics13071021 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pinto, Cristiane M. Horta, Laila S. Soares, Amanda P. Carvalho, Bárbara A. Ferreira, Enio Lages, Eduardo B. Ferreira, Lucas A. M. Faraco, André A. G. Santiago, Helton C. Goulart, Gisele A. C. Nanoencapsulated Doxorubicin Prevents Mucositis Development in Mice |
title | Nanoencapsulated Doxorubicin Prevents Mucositis Development in Mice |
title_full | Nanoencapsulated Doxorubicin Prevents Mucositis Development in Mice |
title_fullStr | Nanoencapsulated Doxorubicin Prevents Mucositis Development in Mice |
title_full_unstemmed | Nanoencapsulated Doxorubicin Prevents Mucositis Development in Mice |
title_short | Nanoencapsulated Doxorubicin Prevents Mucositis Development in Mice |
title_sort | nanoencapsulated doxorubicin prevents mucositis development in mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329927/ https://www.ncbi.nlm.nih.gov/pubmed/34371713 http://dx.doi.org/10.3390/pharmaceutics13071021 |
work_keys_str_mv | AT pintocristianem nanoencapsulateddoxorubicinpreventsmucositisdevelopmentinmice AT hortalailas nanoencapsulateddoxorubicinpreventsmucositisdevelopmentinmice AT soaresamandap nanoencapsulateddoxorubicinpreventsmucositisdevelopmentinmice AT carvalhobarbaraa nanoencapsulateddoxorubicinpreventsmucositisdevelopmentinmice AT ferreiraenio nanoencapsulateddoxorubicinpreventsmucositisdevelopmentinmice AT lageseduardob nanoencapsulateddoxorubicinpreventsmucositisdevelopmentinmice AT ferreiralucasam nanoencapsulateddoxorubicinpreventsmucositisdevelopmentinmice AT faracoandreag nanoencapsulateddoxorubicinpreventsmucositisdevelopmentinmice AT santiagoheltonc nanoencapsulateddoxorubicinpreventsmucositisdevelopmentinmice AT goulartgiseleac nanoencapsulateddoxorubicinpreventsmucositisdevelopmentinmice |